The FMF integrated test is an assessment of an individual’s risk of having a baby with a chromosomal abnormality through the combined testing of ultrasound markers, which are part of the so-called genetic ultrasound, and biochemical markers, from the pregnant woman’s blood.
Ideally, these tests should be performed on the same day, between 11th and 13th + 6 days of pregnancy, when the CRL value is between 45mm and 84mm. This method can detect 85% to 90% of abnormal foetuses in the first trimester of pregnancy. Based on the test results, using special computer software, a diagnostician certified by the FMF to perform the integrated test evaluates the risk of foetal chromosomal anomalies listed below:
- trisomy 18 (Edwards syndrome)
- trisomy 21 (Down syndrome)
- trisomy 13 (Patau syndrome).
As a result, the patient receives a printout of the individual risk of childbirth, with the above-mentioned genetic pathologies, compared to the average risk in the population.
The price of the examination (600 PLN for patients with prenatal and obstetrics package in Medfemina, 700 PLN for patients who do not use prenatal and obstetrics package in Medfemina) includes:
- performing a genetic ultrasound – 250 (350) PLN
- biochemical tests (Pappa, betaHCG on Kryptor apparatus) together with assessment in FMF program and printout – 350 PLN (250 PLN laboratory tests, 100 PLN result processing and risk calculation)
Possible additional consultation of the result with the attending gynaecologist supervising pregnancy, additionally paid – PLN 100